A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. Our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.
| Errataetall: |
UpdateIn: Nat Commun. 2020 Aug 13;11(1):4059. - PMID 32792628 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2020) vom: 22. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Muruato, Antonio E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 28.03.2024 published: Electronic UpdateIn: Nat Commun. 2020 Aug 13;11(1):4059. - PMID 32792628 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.05.21.109546 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310908566 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310908566 | ||
| 003 | DE-627 | ||
| 005 | 20240328235408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.05.21.109546 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM310908566 | ||
| 035 | |a (NLM)32511386 | ||
| 035 | |a (PII)2020.05.21.109546 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Muruato, Antonio E |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Nat Commun. 2020 Aug 13;11(1):4059. - PMID 32792628 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. Our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a vaccine | |
| 700 | 1 | |a Fontes-Garfias, Camila R |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Blanco, Mariano A |e verfasserin |4 aut | |
| 700 | 1 | |a Menachery, Vineet D |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xuping |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Pei-Yong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2020) vom: 22. Mai |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:22 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.05.21.109546 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 22 |c 05 | ||